Where a single Phase 2 data readout can reprice the float 60% in a morning and a CRL can halve it by lunch. Our beat is sub-$300M drug developers, clinical-stage platforms, and the dilution math that sell-side decks quietly leave out.
How masked-antibody design aims to spare healthy tissue in cancer immunotherapy.
Why covalent, irreversible small-molecule binding is having a quiet renaissance.
Why a 50-year treatment plateau in glioblastoma is finally showing cracks.
In vivo gene editing as the next frontier after CRISPR-Cas9.
A different approach to chronic-disease treatment through implantable delivery.
The biology behind KRAS-mutated colorectal cancer and how investors should read the trial data.
The total artificial heart as an underappreciated bridge to transplant — the need and the market.
FDA alignment derisks the most common reason Phase 3 trials fail. What Corbus does with the compressed calendar is the whole equity story.
36-month ARVO readout confirms durability. Rerating to generalist biotech flows needs a second catalyst. What would change the call.
First-cohort biomarker hit for CMND-100 in alcohol use disorder. Three signals to watch through the next two cohorts.
Phase 2b oncolytic-virus data at AACR. But the balance sheet is what actually moves the equity — cash runway analysis and three financing paths.
Ameluz revenue growing high-teens. OpEx flat. Sales-force buildout finally scaling. The textbook commercial-stage inflection — just without the story-stock drama.
Crofelemer's canine CID trial is the first real platform-extension shot. Human vs. veterinary economics are not the same model.